Personalis, Inc.

Personalis, Inc. (PSNL) priced its initial public offering on Jun 20, 2019 at $17.00 per share, above its $14.00–$16.00 range, raising $134.7M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $505.8M. Morgan Stanley was lead-left underwriter, joined by BofA Securities, TD Cowen and Oppenheimer. Cooley advised the company and Davis Polk advised the underwriters.

Personalis, Inc. is a cancer genomics company whose NeXT Platform gives biopharmaceutical customers molecular data on about 20,000 human genes and the immune system for each patient's cancer. It is also developing a liquid biopsy assay that analyzes all human genes.

Status

IPO

Ticker

PSNL

Exchange

Nasdaq Global Market

Priced

Jun 20, 2019

IPO price

$17.00

Price range

$14.00–$16.00

Raised

$134.7M

Market cap at IPO price

$505.8M

First filed

May 23, 2019

Underwriters

Morgan Stanley, BofA Securities, TD Cowen and Oppenheimer

Company counsel

Cooley

Underwriters' counsel

Davis Polk

Sector

Healthcare

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.